Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Case report of ocular squamous neoplasia (recalcitrant case): a novel approach with interferon alpha 2b adjunct with Lucentis (Ranibizumab inj)

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Ocular Pathologies

Session Date/Time: Sunday 11/09/2016 | 15:00-16:30

Paper Time: 16:00

Venue: Poster Village: Pod 4

First Author: : V.Surong INDIA

Co Author(s): :    S. Saikia              

Abstract Details


Ocular surface squamous neoplasia consists of a wide range of both conjunctival and corneal lesions ranging from dysplastic changes to invasive squamous cell carcinoma. Although occurring commonly in the elderly , these lesions are also been reported in young adults. A case report of ocular squamous carcinoma occurring in a young adult female recalcitrant case following excision biopsy with adjunctive treatment with mitomycin. A new approach to treatment was done in this case , following many case reports on treatment of OSSN with topical and subconjunctival interferon alpha 2b and a new adjunctive subconjunctival injection of 0.05ml lucentis.


Mission trust/Bawri Nethralaya (Meghalaya N-E India)


A female patients age 35 years , complaining of irritation and redness on the right eye for one month Presented with conjunctival injection ,limbal growth 3mmx 1.5mm clinically diagnosed as pterygium/ossn, surgical resection with mitomycin 0.04% . Biopsy reported as squamous cell carcinoma After 3 weeks growth,was aggressive vascularisation,feeder vessels and raised plaque in inferior quadrant from 4 to 9.O-clock. Surgical excision was repeated and topical mytomycin four times for two weeks but with no response. interferon alpha 2b (20mcg) subconjunctivally and intralesional was administered alongwith topical drops 10 mcg 4 times and adjunctive with lucentis inj 0.05ml


case was followed for a week clinically regression of growth and vascular core detected clinically and symptoms of foreign body sensation, redness decreased. No reports on any ocular side effects except mild congestion which decreased in a week and systematically no untoward reaction. Patient was followed for 2 weeks and 2nd injection was given along with topical interferon , and patients was closely monitored for the next 2 weeks with 3rd injection of interferon and lucentis. Following periodic check up it observed the extensive vascularised growth had decreased significantly within a short span . patient was on topical interferon for 3 months and was off drugs 6 months. During this period the patient was closely watched for any regrowth.


With this new therapeutic approach we experienced that the growth response to the new treatment, eliminating - surgical excision, cryotherapy and radiation and preserved vision , with no sign of recurrence. This could be an alternative approach to management of ocular squamous cell carcinoma and also hold a promise of achieving a good results. Further more clinical study are necessary to establish the effectiveness of this two drugs to support the above case report.

Financial Disclosure:


Back to previous